These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
337 related articles for article (PubMed ID: 22448595)
41. A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'. Tanasescu R; Rog D; Constantinescu CS Expert Opin Drug Discov; 2011 Apr; 6(4):437-52. PubMed ID: 22646020 [TBL] [Abstract][Full Text] [Related]
42. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease. Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310 [TBL] [Abstract][Full Text] [Related]
43. Cannabinoids in late-onset Alzheimer's disease. Ahmed A; van der Marck MA; van den Elsen G; Olde Rikkert M Clin Pharmacol Ther; 2015 Jun; 97(6):597-606. PubMed ID: 25788394 [TBL] [Abstract][Full Text] [Related]
44. Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease. Xiong Y; Lim CS Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573232 [TBL] [Abstract][Full Text] [Related]
45. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease. Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534 [TBL] [Abstract][Full Text] [Related]
46. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Horváth B; Mukhopadhyay P; Haskó G; Pacher P Am J Pathol; 2012 Feb; 180(2):432-42. PubMed ID: 22155112 [TBL] [Abstract][Full Text] [Related]
47. Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy? Fonseca C; Ettcheto M; Bicker J; Fernandes MJ; Falcão A; Camins A; Fortuna A Ageing Res Rev; 2023 Sep; 90():101998. PubMed ID: 37414155 [TBL] [Abstract][Full Text] [Related]
48. Can We Treat Neuroinflammation in Alzheimer's Disease? Sánchez-Sarasúa S; Fernández-Pérez I; Espinosa-Fernández V; Sánchez-Pérez AM; Ledesma JC Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228179 [TBL] [Abstract][Full Text] [Related]
49. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy. Abate G; Uberti D; Tambaro S Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34204237 [TBL] [Abstract][Full Text] [Related]
50. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents. Ambure P; Roy K Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675 [TBL] [Abstract][Full Text] [Related]
51. Endocannabinoid system, pharmacogenomics and response to therapy. Onaivi ES Pharmacogenomics; 2010 Jul; 11(7):907-10. PubMed ID: 20602608 [No Abstract] [Full Text] [Related]
52. Therapeutic links between Alzheimer's disease and brain cancer: drug discovery consequences. Kraus JL ChemMedChem; 2013 May; 8(5):689-92. PubMed ID: 23444291 [TBL] [Abstract][Full Text] [Related]
53. Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations. Xu J; Kong X; Qiu L; Geng X; Hu Y; Wang Y Expert Opin Ther Pat; 2014 Jul; 24(7):791-800. PubMed ID: 24798577 [TBL] [Abstract][Full Text] [Related]
54. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study. Koppel J; Bradshaw H; Goldberg TE; Khalili H; Marambaud P; Walker MJ; Pazos M; Gordon ML; Christen E; Davies P Lipids Health Dis; 2009 Jan; 8():2. PubMed ID: 19144193 [TBL] [Abstract][Full Text] [Related]
55. Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention? Marchalant Y; Baranger K; Wenk GL; Khrestchatisky M; Rivera S J Neuroinflammation; 2012 Jan; 9():10. PubMed ID: 22248015 [TBL] [Abstract][Full Text] [Related]